Daix (France), Long Island City (New York, United States), November 21, 2022
– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with a need unsatisfied doctor, announces today the cooptation of Dr. Lucy Lu as Director within its Board of Directors, as of November 9, 2022, in place of Sofinnova Partners.
The appointment of Dr. Lucy Lu will be submitted to the shareholders for ratification at the next Inventiva General Meeting.
Dr. Lucy Lu has been the Sofinnova Partners representative on the Inventiva Board of Directors since January 4, 2020. Dr. Lu has a broad experience of more than 20 years in the biotechnology and healthcare sectors in as an investment banker, financial analyst and managing director. Dr. Lu is Chief Operating Officer at Innovative Cellular Therapeutics and was previously President and CEO of Avenue Therapeutics. Dr. Lu has also worked as a biotechnology financial analyst for Citigroup Inc. and holds an MD from the
New York University School of Medicine.
Frédéric Cren, Chairman and CEO and co-founder of Inventiva, commented
:
“We are very pleased to appoint Dr. Lu as Director of the Board of Inventiva. Dr. Lu has been on the Board for almost three years, and his global knowledge of the sector is a great asset to the Company, in particular with the development of lanifibranor and the signing of a first license agreement for the development and marketing of lanifibranor in Greater China. On behalf of the Board of Directors, I would like to thank Dr. Lu for his continued participation on the Board, and I also thank Sofinnova Partners for their contribution to Inventiva’s success over the past three years. »
About Inventiva
Inventiva is a biopharmaceutical company specializing in the research and development of orally administered small molecules for the treatment of patients with NASH, MPS and other diseases with significant unmet medical needs. The Company has significant experience and expertise in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently developing a clinical candidate, has a portfolio of two preclinical programs and continues to explore other development opportunities to expand its portfolio.
Lanifibranor, Inventiva’s most advanced drug candidate, is currently being evaluated in the pivotal Phase III NATiV3 clinical study for the treatment of adult patients with NASH, a common and progressive chronic liver disease, for which it is there is currently no approved treatment.
In 2020, Inventiva published positive results from its Phase IIb clinical study evaluating lanifibranor for the treatment of patients with NASH and obtained the status of “
Breakthrough Therapy
” and of ”
FastTrack
” of the
Food and Drug Administration
(FDA) for lanifibranor in the treatment of NASH.
Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) type VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended its clinical efforts with odiparcil and is reviewing all available options to optimize its development. Inventiva is in the process of selecting a drug candidate in oncology as part of its program dedicated to the Hippo signaling pathway.
The Company has a scientific team of approximately 80 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. Inventiva has a chemical library of around 240,000 molecules, of which around 60% are exclusive to the Company, as well as its own laboratories and equipment.
Inventiva is listed on compartment C of the regulated market of Euronext Paris (Euronext Paris: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
www.inventivapharma.com
.
contacts
|
inventive Pascaline Clerc [email protected] |
Brunswick Group Laurence Frost / Tristan Roquet Montegon / Aude-Lepreux Media relations [email protected] +33 1 53 96 83 83 |
Westwicke, an ICR Company Patricia L. Bank Investor Relations [email protected] +1 415 513-1284 |
Warning
This press release contains forward-looking statements. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates relating to Inventiva’s pre-clinical and clinical programs, including recruitment and screening for such clinical trials, including the Phase III clinical trial. NATiV3 for the treatment of lanifibranor in NASH, potential development and regulatory journey for odiparcil, publications of clinical data, information, analysis and impact that can be gathered through clinical trials, therapeutic benefits potential of lanifibranor, the contract entered into between the Company and Sino Biopharm, pipeline, and preclinical or clinical development plans, future activities, expectations, plans, growth and forecasts of the Company and sufficient liquidity and funding horizon. Some of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “projects”, “plans”, “seeks”, “estimates”, “may”, “wants” and “continues” and other similar expressions. These statements do not relate to proven historical facts, but constitute projections, estimates and other forward-looking data based on management’s opinions, expectations regarding the potential commercial success and potential revenues of Inventiva’s drug candidates. These statements reflect the opinions and assumptions that were made on the date they were made. They are subject to known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those indicated or implied by such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva’s control. With respect to the pipeline of product candidates, there can be no assurance that the results of clinical studies will be available on schedule, that future clinical studies will be launched as planned, or that these candidates will receive the necessary regulatory approvals. . Actual results may differ from future results described, implied or anticipated in such forward-looking statements due to a number of important factors, including that Inventiva is a clinical-stage company with no approved products and who does not have a history of revenue generated from the sale of products. These factors include, in particular, the significant losses generated since the creation of Inventiva, a limited operating history, the absence of income generated by the sale of Inventiva’s products, the need for additional funds to finance its operations. Inventiva’s future success also depends on the successful clinical development, receipt of regulatory approvals and subsequent commercialization of its current and future product candidates. Preclinical studies or prior clinical trials are not necessarily predictive of future results, and the results of Inventiva’s clinical trials may not support the reported benefits of Inventiva’s product candidates. Inventiva may experience significant delays in its clinical trials or Inventiva may fail to demonstrate the safety and efficacy of its products to the relevant regulatory authorities. Recruiting and retaining patients in clinical trials is a time-consuming and costly process that could be made more difficult or impossible by multiple factors beyond Inventiva’s control. Inventiva’s product candidates could cause adverse effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition, and the activities, preclinical studies and development programs Inventiva’s clinical development as well as timelines, its financial condition and results of operations could be materially affected by the COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, which could delay the initiation, recruitment and completion of Inventiva’s clinical trials on schedule or delaying them. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of this release. Readers are therefore cautioned not to place undue reliance on these forward-looking statements.
We invite you to refer to the Universal Registration Document for the financial year ended December 31, 2021 filed with the Autorité des marchés financiers on March 11, 2022 and to the financial report for the first half of 2022 for additional information concerning these factors, risks and uncertainties.
Subject to applicable regulations, Inventiva makes no commitment to update or revise the information contained in this press release. Inventiva cannot therefore be held liable for
consequences that may result from the use that would be made of these declarations.
Attachment
Inventiva – PR – Board of Directors – 21 11 2022